PREVAIL IV: Double-Blind, Randomized, Two-Phase, Placebo-Controlled, Phase II Trial of GS-5734 to Assess the Antiviral Activity, Longer-Term Clearance of Ebola Virus, and Safety in Male Ebola Survivors With Evidence of Ebola Virus Persistence in Semen
Phase of Trial: Phase II
Latest Information Update: 09 Nov 2017
At a glance
- Drugs GS 5734 (Primary)
- Indications Ebola virus infections
- Focus Therapeutic Use
- Acronyms PREVAIL IV
- 24 Jun 2017 Planned End Date changed from 1 Jun 2018 to 26 Jan 2018.
- 24 Jun 2017 Planned primary completion date changed from 1 Jun 2018 to 29 Dec 2019.
- 26 Apr 2017 Planned End Date changed from 1 Nov 2017 to 1 Jun 2018.